Use of known compounds as d-amino acid oxidase inhibitors

作者: Chung-Ming Sun , Wen-Sung Lai , Yufeng Jane Tseng , Chih-Min Liu , Hai-Gwo Hwu

DOI:

关键词:

摘要: The invention utilizes virtual screening strategy to seek for current market drugs as anti-schizophrenia therapy drug repurposing. Drug repurposing finds new uses other than the original medical indications of existing drugs. Finding such will benefit patients who are in needs a potential sooner since known usually with acceptable safety and pharmacokinetic profiles. In this study, marketed DAAO inhibitor schizophrenia was performed on its metabolites. identified available compounds were further confirmed vitro enzymatic inhibitory assay.

参考文章(29)
Alfredo Cugola, Giovanni Gaviraghi, Indole derivatives and pharmaceutical use thereof ,(1993)
Alex A. Cordi, William F. Hood, Brian K. Cheng, Nancy M. Gray, Michael S. Dappen, Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders ,(1992)
Charles Zepp, Donald Heefner, Richard Rossi, Mark Currie, D-amino acid oxidase inhibitors for learning and memory ,(2002)
Daniela Alberati, Joseph G. Wettstein, Jean-Luc Moreau, Combination of glyt1 compound with antipsychotics ,(2011)
Charlotte Fieldhouse, Katherine Hazel, William Farnaby, David Livermore, Catrina Kerr, Kevin Merchant, Natasha Kinsella, David Miller, Pyridazinone compounds and their use as daao inhibitors ,(2012)
Joseph T. Coyle, I-Ching Tsai, Pinchen Yang, Chung-Wen Tsai, Li-Chen Chung, Guochuan E. Tsai, D-serine added to clozapine for the treatment of schizophrenia. American Journal of Psychiatry. ,vol. 156, pp. 1822- 1825 ,(1999) , 10.1176/AJP.156.11.1822
Paul A. Novick, Oscar F. Ortiz, Jared Poelman, Amir Y. Abdulhay, Vijay S. Pande, SWEETLEAD: an In Silico Database of Approved Drugs, Regulated Chemicals, and Herbal Isolates for Computer-Aided Drug Discovery PLoS ONE. ,vol. 8, pp. e79568- ,(2013) , 10.1371/JOURNAL.PONE.0079568
Quan Zhou, Li, Yu, Zeng, Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management. Therapeutics and Clinical Risk Management. ,vol. 9, pp. 259- 271 ,(2013) , 10.2147/TCRM.S43151